Eisai's hhc (human health care) mission is to give first thoughts to patients and their families by developing drugs for diseases with significant unmet medical need. Nowhere is this more compelling than in oncology, one of Eisai's long-standing therapeutic areas of focus since 1987.
Eisai continues to grow its commitment to oncology—in research and clinical development, in approved treatments for cancer and supportive care, and in enhanced manufacturing capabilities. Eisai has a diverse in-house pipeline of oncology compounds in development and several more about to begin clinical trials. Please visit our clinical trials area for information about open Eisai oncology studies.
In April 2007, Eisai acquired Morphotek, Inc. (www.morphotek.com) , a company based in Exton, Pennsylvania. Morphotek develops therapeutic monoclonal antibodies through the use of its proprietary human antibody technologies, Human MORPHODOMA® and LibradomaTM. Morphotek is leveraging these technologies to enrich its pipeline that currently includes antibody candidates for the treatment of cancer, rheumatoid arthritis and infectious disease.
In addition to chemotherapeutic agents, small molecules, biologics and supportive care products, the Morphotek acquisition expands Eisai's capabilities to help address a variety of unmet medical needs of cancer patients through the development of therapeutic antibodies.
The expansion of Eisai's oncology discovery, research and clinical capabilities complements the Company's establishment of its oncology sales and marketing operations in the United States. The acquisition of four marketed products in October 2006, as well as key oncology personnel and expertise, including a sales force, laid the foundation for Eisai's U.S. oncology sales and marketing operation. Eisai acquired exclusive global rights to three marketed products for the treatment of cutaneous T-cell lymphoma (CTCL) and one for the treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS).
Eisai is committed to enhancing its commercial oncology infrastructure. The organization is well positioned to market new oncology products that originate from Eisai's research and discovery efforts or through future acquisition, co-promotion or in-licensing opportunities.